Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation

• Status: Not yet recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk non-muscle-invasive bladder cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ankara Training and Research Hospital
• Treatments: Epirubicin; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Low and intermediate risk NMIBC

Exclusion Criteria:

• High risk NMIBC

• Patients who received intravesical BCG

• Postoperative gross hematuria

• Bladder perforation

• Pregnancy

• Urinary tract infection

• Epirubicin allergy